TIL与顺铂治疗恶性胸腔积液的疗效比较  

The Effects of Tumor Infiltrating Lymphocytes for Treatment of Malignant Pleural Effusion Compare to Cisplatin

作　　者：陈建清[1] 康美玲[1] 钟小红[1] 曾道林[1] 刘进兵[1] 吴晓安[1] 

机构地区：[1]解放军第一七四医院肿瘤中心二区,361003

出　　处：《实用癌症杂志》2011年第1期53-55,共3页The Practical Journal of Cancer

摘　　要：目的观察肿瘤浸润淋巴细胞(TIL)与顺铂治疗恶性胸腔积液的疗效。方法 40例患者随机选取20例为试验组、对照组,从恶性肿瘤胸腔积液的肿瘤细胞中分离得到TIL,并经10%人AB血清RPMI-1640液培养,经rIL-2体外激活培养,随后胸腔注射;对照组抽取胸腔积液后用顺铂胸腔注射。结果试验组完全缓解8例(40%),有效10例(50%),无效2例(10%),总有效率90%(18/20);对照组完全缓解7例(35%),有效9例(45%),无效4例(20%),总有效率80%(16/20)。两者疗效无统计学意义(P>0.05)。不良反应轻。结论 TIL治疗恶性胸腔积液疗效好,毒副作用小,能改善患者的生活质量。Objective To evaluate the effect of tumor infilitrating lymphocytes（TIL） in the treatment of patients with malignant pleural effusion.Methods 40 patients with malignant pleural effusion were randomly divided into two groups.TILs were derived from malignant pleural effusion in the study group,and then cultivated in the 10% AB type serum RPMI-1640 liquid,and activated by rIL-2 in vitro.The TILs were then injected into thoracic cavities.Patients in the control group were given cisplatin after removal of the pleural effusion.Results The CR,PR,and NR were 8（40%）,10（50%） and 2（10%） in the study group,with an overall response rate of 90%（18/20）;whereas the CR,PR,and NR were 7（35%）,9（45%） and 4（20%）,with an overall response rate was 80%（16/20）.The response rate in the two groups had no significant difference.Conclusion Infusion of TILs derived from malignant pleural is safe and effective in the treatment of patients with malignant pleural.

关 键 词：恶性肿瘤 肿瘤浸润细胞 顺铂 胸腔积液 穿刺术 

分 类 号：R730.6[医药卫生—肿瘤]